Literature DB >> 7471316

Early detection of doxorubicin cardiotoxicity by M-mode echocardiography.

W Markiewicz, E Robinson, B Peled, S Kaufman, A Carter.   

Abstract

The influence of increasing doses of doxorubicin on the heart was examined in 30 patients with solid tumors, M-mode echocardiography being used to evaluate left ventricular contractility. The function of the left ventricle remained normal in 26 subjects, whereas four patients had evidence of cardiotoxicity after cumulative doses of 220, 380, 420, and 450 mg/m2. Transient overt heart failure was noted in one subject only. Doxorubicin cardiotoxicity can be detected by M-mode echocardiography, a simple and non-invasive technique, prior to the appearance of overt congestive heart failure. Patients demonstrating left ventricular dysfunction are probably not candidates for receiving further therapy with anthracycline antibiotics. Limitation of M-mode echocardiography include a 28% incidence of inadequate studies in this group of patients, and a relative inaccuracy of the technique in evaluating patients with prior myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7471316     DOI: 10.1007/bf00435415

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  Measurement of left ventricular ejection fraction by mechanical cross-sectional echocardiography.

Authors:  K W Carr; R L Engler; J R Forsythe; A D Johnson; B Gosink
Journal:  Circulation       Date:  1979-06       Impact factor: 29.690

2.  Analysis of left ventricular wall motion by reflected ultrasound. Application to assessment of myocardial function.

Authors:  I G McDonald; H Feigenbaum; S Chang
Journal:  Circulation       Date:  1972-07       Impact factor: 29.690

3.  Contribuiton of M-mode echocardiography to cardiac diagnosis. An assessment in 1,000 successive patients.

Authors:  W Markiewicz; B Peled; H Hammerman; Z Greif; J Hir; E Riss
Journal:  Am J Med       Date:  1978-11       Impact factor: 4.965

4.  Effect of transducer placement on echocardiographic measurement of left ventricular dimensions.

Authors:  R L Popp; K Filly; O R Brown; D C Harrison
Journal:  Am J Cardiol       Date:  1975-04       Impact factor: 2.778

5.  Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization.

Authors:  M R Bristow; J W Mason; M E Billingham; J R Daniels
Journal:  Ann Intern Med       Date:  1978-02       Impact factor: 25.391

6.  Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.

Authors:  D D Von Hoff; M Rozencweig; M Layard; M Slavik; F M Muggia
Journal:  Am J Med       Date:  1977-02       Impact factor: 4.965

7.  Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.

Authors:  J Alexander; N Dainiak; H J Berger; L Goldman; D Johnstone; L Reduto; T Duffy; P Schwartz; A Gottschalk; B L Zaret
Journal:  N Engl J Med       Date:  1979-02-08       Impact factor: 91.245

8.  Anthracycline cardiomyopathy monitored by morphologic changes.

Authors:  M E Billingham; J W Mason; M R Bristow; J R Daniels
Journal:  Cancer Treat Rep       Date:  1978-06

9.  Serial studies of cardiac function in patients receiving adriamycin.

Authors:  I C Henderson; L J Sloss; N Jaffe; R H Blum; E Frei
Journal:  Cancer Treat Rep       Date:  1978-06

10.  Echocardiography in adriamycin cardiotoxicity.

Authors:  K R Bloom; R M Bini; C M Williams; M J Sonley; M A Gribbin
Journal:  Cancer       Date:  1978-04       Impact factor: 6.860

View more
  2 in total

1.  Comparative Therapeutic Potential of Cardioactive Glycosides in Doxorubicin Model of Heart Failure.

Authors:  Raquel da Silva Ferreira; Paula Bretas Ullmann Fernandes; Jéssica Pereira Oliveira da Cruz; Françoise Louanne Araújo Silva; Marthin Raboch Lempek; Gioavanni Naves Canta; Júlio César Cambraia Veado; Matheus Matioli Mantovani; Ana Flávia Machado Botelho; Marília Martins Melo
Journal:  Cardiovasc Toxicol       Date:  2021-10-16       Impact factor: 3.231

2.  [Possible prevention of adriamycin-induced cardiomyopathy by verapamil. Results of a pilot study].

Authors:  U Müllerleile; M Garbrecht; P Hanrath; B A Langenstein; K Bieber; W Bleifeld; D K Hossfeld
Journal:  Klin Wochenschr       Date:  1984-11-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.